Royalty Pharma plc (NASDAQ:RPRX) Q3 2022 Earnings Call Transcript

Marshall Urist: A lot of those questions on the ad com and the label and where it might go are probably great questions for Cytokinetics. We’ve had a really great partnership with Cytokinetics over the years in terms of our initial deal on omecamtiv and then our synthetic royalty transaction on aficamten earlier this year. So, we really believe in the Cytokinetics team, they’ve been executing really well. We’ll look out for what happens at the ad com and then ultimately next year on the PDUFA date. But I think big picture, we think this product does have the potential to help patients who have severe heart failure and look forward to watching what happens in the months to come.

Operator: There are no further questions. I’d like to turn the call over to Pablo Legorreta for closing remarks.

Pablo Legorreta: Thank you, operator. And thank you to everyone on the call for your continuing interest in Royalty Pharma. If you have any follow-up questions, please feel free to reach out to George Grofik and his team.

Operator: This concludes the program. You may now disconnect. Everyone, have a great day.